NASDAQ · FDMT
4D Molecular Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FDMT: Nov 9, 2026
4D Molecular Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.03. The reported EPS for the same quarter last year was $-1.01.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.03 | $-0.99 | $-1.07 | 4 |
| Dec 2026 | $-1.03 | $-0.99 | $-1.10 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · BNK Invest · RTTNews · Zacks- MarketBeat · Oct 22, 7:02 AM EDT4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy4D Molecular Therapeutics (NASDAQ:FDMT) used its first Investor Day to outline its development and commercial plans for 4D-150, an investigational intravitreal gene therapy for wet age-related macular degeneration, or wet AMD. Company executives and retina specialists described t
- BNK Invest · Oct 5, 5:05 PM EDT4D Molecular Therapeutics Becomes Oversold (FDMT)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Sep 28, 12:21 PM EDT4D Molecular Enrolls First Patient In Phase 3 4SIGHT Trial, Reports Durable 2-Year SPECTRA Data(RTTNews) – 4D Molecular Therapeutics Inc. (FDMT) a late-stage biotechnology company announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema. In addition, the com
- RTTNews · Aug 17, 2:50 PM EDTTop Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News(RTTNews) – Today's top gainers in the biotech and medical technology space include 4D Molecular Therapeutics, following Phase 3 progress and strong clinical data; OmniAb, after securing a collaboration with Eli Lilly and raising its cash outlook; Acurx Pharmaceuticals, following
- Zacks · Aug 13, 6:05 PM EDT4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 13, 8:15 AM EDTMediWound (MDWD) Reports Q2 Loss, Beats Revenue EstimatesMediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTCollegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue EstimatesCollegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 9:00 AM EDTBioventus (BVS) Q2 Earnings Meet EstimatesBioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 7:20 AM EDTAmneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass EstimatesAmneal (AMRX) delivered earnings and revenue surprises of +25.00% and +3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 24, 11:02 AM EDTWeekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data(RTTNews) – This week, the biotech sector was marked by FDA and EU approvals, strategic acquisitions, and a major workforce restructuring. Clinical trial updates delivered both breakthroughs and setbacks across oncology, obesity, and dermatology, underscoring the sector's volatil
- RTTNews · Jul 20, 4:48 AM EDT4D Reports Positive 2-Year Phase 2b Data For 4D-150 In Wet AMD(RTTNews) – 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company, announced positive 2-year data from the Phase 1/2 PRISM trial, including a Phase 2b cohort evaluating 4D-150 in patients with wet age-related macular degeneration.
- Zacks · Jun 23, 9:42 AM EDTStrength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for 4D Molecular Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.